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Abstract: The current literature describes the possible risks for bone fracture in chronic 
analgesics users. There are three main hypotheses that could explain the increased risk of frac-
ture associated with central analgesics, such as opioids: 1) the increased risk of falls caused by 
central nervous system effects, including sedation and dizziness; 2) reduced bone mass density 
caused by the direct opioid effect on osteoblasts; and 3) chronic opioid-induced hypogonadism. 
The impact of opioids varies by sex and among the type of opioid used (less, for example, for 
tapentadol and buprenorphine). Opioid-associated androgen deficiency is correlated with an 
increased risk of osteoporosis; thus, despite that standards have not been established for moni-
toring and treating opioid-induced hypogonadism or hypoadrenalism, all patients chronically 
taking opioids (particularly at doses $100 mg morphine daily) should be monitored for the 
early detection of hormonal impairment and low bone mass density.
Keywords: opioids side effects, bone metabolism, fractures, OPIAD, endocrine system, 
chronic pain
Introduction
Severe chronic pain still represents a challenge for physicians, as it profoundly affects 
not only the quality of life of patients and their health and mental status, but it also 
impacts their ability to work and represents a huge economic burden for our society. 
Data from a European survey suggest that about 25% of the population experiences 
chronic pain that affects the muscles, joints, neck, or back, lasting for more than 
3 months.1 The increased prevalence of other comorbidities, such as anxiety and 
depression, may further exacerbate the impact of chronic pain on patients and may 
decrease their physical and mental functioning.2 Chronic pain has been recognized as 
involving the phenomena of central sensitization and neuroplasticity, which alter the 
physiological transduction and perception of nociceptive stimuli.3
In clinical practice, pain is classified as acute or chronic, only on the basis of its 
duration, and analgesics are often chosen only on the basis of pain intensity (eg, mild, 
moderate, or severe), as suggested by the World Health Organization’s analgesic 
ladder.4 This approach is, however, not informative, because pain intensity does not 
reflect the neurobiological cause. Chronic pain is an expression of a dysfunction of 
the peripheral or central nervous system (CNS); therefore, treatment strategies should 
shift from the existing strategy of symptom control to a mechanism-oriented approach. 
This new approach represents an epochal change in the management of chronic pain5,6 
and opens the door to a wider use of central analgesics, including opioids, which better 
fit with the real needs of chronic pain patients.
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Unfortunately, the recent literature suggests the possible 
risks to bone and its functions in chronic opioid analgesics 
users.7 This review aims to analyze the current hypotheses 
by which opioids could be considered “bone-impairing 
analgesics”.
The first possible connection: 
increased number of falls
In recent years significant differences have been observed 
between subjects exposed to long-term pain medication use 
and nonusers in terms of the incidence of bone fractures and 
fall-related injuries. This supports the idea that analgesics, 
particularly centrally acting drugs, may indirectly affect bone 
through fall-related fractures caused by effects on the CNS, 
such as dizziness and sedation. Among analgesics, opioids 
have been frequently associated with an increased risk of 
fall-related fractures, particularly in the elderly.8 Indeed, 
fall-related fractures are the sixth leading cause of death 
among older adults.9
Managing chronic pain in the elderly by using weak opi-
oids or low doses of strong opioids may be safer than using 
nonsteroidal anti-inflammatory drugs (NSAIDs) because 
opioids do not impair organ function, which may be declined 
in these patients.10 However, opioids may increase somnolence 
and confusion, which play a role in increasing the risk of falls 
of people in older age.11 For example, Ensrud et al12 evaluated 
a cohort of more than 8,000 elderly women taking narcotics 
and reported a significant increase in the risk of nonspine frac-
tures (hazard ratio [HR]: 1.40), probably related to the cogni-
tive effects of such drugs. Similar results have been found 
in Denmark in a nationwide registry-based study of about 
125,000 cases of fractures: all examined opioids increased 
the risk of fractures, except buprenorphine, pethidine, dextro-
propoxyphene, and combinations of acetylsalicylic acid and 
codeine.13 The increased incidence of fractures was observed, 
even in the first days of treatment, during the titration phase, 
when opioid doses are low. Therefore, despite most of these 
fractures involving typical osteoporotic localizations such as 
the spine, hip, and forearm, it is unlikely that they could be 
the result of a direct effect on bone structure – they are more 
likely related to the risk of falls due to CNS effects.13 A recent 
epidemiological study based on the United Kingdom General 
Practice Research Database, where data between January 1, 
1990 and December 31, 2008 have been analyzed, showed 
a direct relationship between the cumulative dose of opioid 
administration and risk of fracture. However, while a single 
opioid prescription increased the risk about threefold (odds 
ratio [OR]: 2.70; 95% confidence interval [CI]: 2.34–3.13), 
the risk decreased (OR: 1.17; 95% CI: 1.08–1.27) when opi-
oid therapy was maintained over time. Patients taking more 
than 20 prescriptions of opioids or patients that ended opioid 
use more than 1 month before injuries had no increased risk 
of fracture. These results support the hypothesis of the CNS 
effects of opioids, which most frequently occur during titra-
tion, when the right dose for each patient has to be found. 
Usually, CNS symptoms resolve in the first days/weeks of 
treatment because of adequate titration or even opioid toler-
ance development; however, special precautions should be 
taken in frail individuals, such as the elderly, patients with 
dementia, or people taking other sedating medications.14 
According to a Canadian study of 400,000 patients, there is 
a wide use of drugs with sedative effects among the elderly 
(at least one drug prescribed in more than 50% of the study 
population over a 1-year follow-up).8 Among the examined 
cases, 15.3% were taking opioids and 20.7% were taking 
more than one sedative medication. The incidence of injuries 
was relatively low (3.7%), but the majority were fractures 
(55.1%). When considering second-step opioids, combina-
tions containing codeine were associated with the highest 
risk of injury (HR: 2.27).8 These studies provide evidence of 
a relationship between opioid and fall-related injury. This is 
probably related to an effect on the CNS, such as dizziness 
or an altered state of consciousness.
Therefore, opioids are not the only CNS drugs to be 
associated with an increased risk of fractures and fall-
related injuries; antipsychotic agents, benzodiazepines,15 and 
antidepressants may also increase the risk of fractures by 
25% (HR: 1.25).12 However, both the likelihood of weakened 
bones and multiple medications in the elderly increase the 
risk of fractures.
A further confounding factor comes from the evidence 
that NSAID users also have a slightly increased risk of frac-
tures when compared to nonusers (HR: 1.44). In a 10-year 
follow-up of more than 2,000 perimenopausal women taking 
analgesics, no statistically significant differences were 
observed in bone mineral density (BMD) alterations, but 
NSAID users were more prone to fractures, while the use of 
paracetamol and opioids was not associated with a significant 
trend toward more fractures. Similarly, no increased risk was 
recorded for aspirin users.16
The second possible connection: 
reduced bone density
A more recent approach to understanding the increased risk 
of fractures among chronic analgesics users includes the 
evaluation of the quality of the broken bone and, therefore, 
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the close relationship between pain medication use, endocrine 
changes, and reduced bone density.
Bone is a living tissue that undergoes a remodeling pro-
cess in order to maintain a balance between formation and 
resorption. Two types of cells are involved in this process: 
the mesenchymal-derived osteoblasts, which synthesize new 
bone matrix; and the monocyte/macrophage-derived osteo-
clasts (for bone resorption). Osteoclasts express cathepsin K, 
vitronectin receptor, and tartrate-resistant acid phosphatase, 
whereas osteoblasts express alkaline phosphatase, type I 
collagen, and osteocalcin. Osteocytes are cells of the mature 
bone, derived from osteoblasts, embedded within the mineral-
ized bone matrix. The activity of these cells is regulated by 
numerous factors, including cytokines in the local environ-
ment, vitamins, growth factors, and systemic hormones.17
Bone remodeling, which is essential to maintain bone 
strength, consists of four phases: activation; resorption; 
reversal; and formation. On the surface of trabecular bone 
or in cortical bone, osteoclasts are activated and initiate the 
“resorption” phase, during which there are only mononuclear 
cells. The “reversal” phase is an intermediate period between 
osteoclast-mediated resorption and osteoblast-mediated forma-
tion, during which osteogenic signals released by osteoclasts 
activate the bone surface and bone marrow cells; they also 
guarantee the coupling process. Once osteoblasts are recruited, 
the “formation” phase starts, during which osteoblasts pro-
duce bone matrix. When the precise balance of these four 
phases is lost in favor of resorption, the result is bone loss, 
as in a number of bone diseases, including osteoporosis.18,19 
In addition to bisphosphonates, which represent the current 
gold standard of therapy, a number of potential new drugs 
are under investigation for the treatment of osteoporosis and 
bone metastases. New molecular targets have been identified 
in bone biology, such as the cytokine receptor triad formed 
by the receptor activator of nuclear factor kappa-B (NF-kB) 
ligand (RANKL)–receptor activator of NF-kB (RANK)–
osteoprotegerin, for which a drug is already available for 
clinical use (denosumab), and others for which medications 
are still in Phase I, II, or III of development.20–22
Medication-induced osteoporosis is an emerging health 
problem related to a number of commonly used drugs, such as 
selective serotonin receptor inhibitors, anticonvulsants, gluco-
corticoids, proton pump inhibitors, and others. Chronic use of 
these medications increases the risk of reduced bone mineral 
density (BMD) and fractures, particularly when patients are 
polymedicated with more than one of these drugs.23
Opioids have been recognized as a risk factor for the 
development of osteoporosis for more than 10 years.24 Other 
CNS-active medications, such as anticonvulsants, have also 
been associated with a significant reduction in BMD, while 
benzodiazepines and antidepressants have not.25 On anti-
depressants in particular, the evidence is discordant, as a 
recent study on male osteoporosis showed that opioids, 
glucocorticoids, and also antidepressants increased osteo-
porosis risk.26
The mechanism by which opioids increase the risk 
of fractures by interfering with bone density is related to 
both direct and indirect effects on bone metabolism: 1) by 
the direct presence of opioid receptors on osteoblasts; and 
2) by the interference with the complex mechanisms that 
physiologically regulate bone turnover (Figure 1).
A number of experimental studies on animal and human 
cells show that opioids can reduce BMD by directly interfer-
ing with osteoblast activity.27–29 Indeed, opioid receptors that 
are present on murine osteoblasts and proenkephalin-derived 
peptides may inhibit the activity of alkaline phosphatase in rat 
osteosarcoma-derived cell lines.28 Similarly, in humans, opioids 
are thought to interfere with the growth of osteoblasts since they 
reduced the levels of serum osteocalcin, which is a marker of 
osteoblast activity. In human osteoblast-like cells (MG-63), 
all the three types of opioid receptor subtypes have been 
identified: mu (MOR); delta (DOR); and kappa (KOR). When 
incubated with morphine, osteocalcin synthesis is significantly 
reduced, while alkaline phosphatase secretion is not affected, 
and naloxone completely reverses the effect of morphine on 
these cells.27 Similarly, there are low serum osteocalcin levels 
in heroin- and cocaine-abusing women when pregnant, as well 
as in the umbilical arteries of their newborns, suggesting a toxic 
effect of these illicit drugs on osteoblasts.29
There seem to be some exceptions, or at least reduced 
effects, among analgesics. For example, in adult female 
rats, chronic use of tramadol was shown to have a lower 
osteoporotic effect than morphine or fentanyl.30 This might 
be explained by the lower affinity for MOR compared to the 
other agonists. It might also relate to the multimechanistic 
nature of tramadol (opioid plus nonopioid). If so, the osteo-
porotic potential of different opioids may vary, and the choice 
of drug can be crucial, particularly in patients with a well-
known diagnosis of, or at an increased risk of, osteoporosis.30 
Accordingly, it is reasonable to think that analgesics with dual 
mechanisms of action, such as tapentadol or even buprenor-
phine, could have a better profile in reducing the impact of 
opioids on bone density. However, further clinical studies 
are warranted to support these findings.
Evidence also indicates that opioids influence the com-
plex system that physiologically modulates bone turnover, 
Therapeutics and Clinical Risk Management 2015:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
518
Coluzzi et al
???????
?????? ????????
????????????
????????????
??????????????
??????
???
?????????????????????????????
????????????????? ???????????????????????????
???????????????????????
????????????????????????????????????????????????????
???????????????????????????????????????????????
Figure 1 Mechanisms by which opioids may increase the risk of fracture and fall-related injuries.
Abbreviations: CnS, central nervous system; GnRH, gonadotropin-releasing hormone; LH, luteinizing hormone; FSH, follicle-stimulating hormone; DHEAS, 
dehydroepiandrosterone sulfate; BMD, bone mass density.
leading to opioid-induced osteoporosis and opioid-associated 
bone fractures. Most data come from patients using intrath-
ecal opioids and from heroin addicts; these subjects are 
exposed to an increased risk of endocrinopathies, which are 
often undetected. Usually, these effects are reversible, but 
chronic use may lead to serious symptoms when the diagnosis 
is missed.31,32
The endocrine effects of opioids primarily include 
the inhibition of the hypothalamic, pituitary, and gonadal 
hormones, and hypothalamic–pituitary–adrenal axis 
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dysfunction.33 Both sexes are exposed to this risk; hypogo-
nadism has been observed after the chronic use of opioids, 
and it is related to the central suppression of the hypothalamic 
secretion of gonadotropin-releasing hormone; decreased pitu-
itary luteinizing hormone (LH), follicle-stimulating hormone 
(FSH), adrenal dehydroepiandrosterone and testosterone, and 
progesterone and estradiol in women; as well as decreased 
testicular testosterone in men.34
In women, ovarian sex hormones may be inhibited 
by the chronic use of opioids; in premenopausal patients, 
LH and FSH may be reduced by 30%, while in postmeno-
pausal patients, they may be reduced to only one-third of 
normal. Similarly, adrenal androgen production, measured 
as the free testosterone level, may be reduced by 40% in 
opioid users.35 This opioid-induced “hormone dysregula-
tion”, observed with controlled-release oral and transdermal 
formulations, may lead to menstrual irregularities, reduced 
fertility, sexual dysfunction, fatigue, depression, a loss of 
muscle strength and mass, and osteoporosis.
In menopause, there is a natural decline in estrogen levels, 
which increases the risk of osteoporosis, characterized by low 
BMD and deterioration of the architectural structure of the 
bones.18 This is the main reason why up to 50% of women are 
likely to have a fracture after the age of 50 years, compared to 
only 20% of men.36 Indeed, the incidence of osteoporosis is 
significantly lower in men; they are protected against osteo-
porotic fractures by greater bone strength, in terms of both 
cortical bone expansion and trabecular bone volume, which 
matured during the pubertal time and have been maintained 
during aging by sufficient estrogen levels. Androgens exert 
further protection against fractures via their anabolic effects 
on muscle mass.36
Chronic opioid users are prone to develop alterations 
in the hypothalamic–pituitary–gonadal axis, which can 
result in hypogonadotropic hypogonadism. This condition, 
named opioid-induced androgen deficiency (OPIAD), has 
been observed in more than 5 million men suffering from 
chronic noncancer pain in the Unites States.37 These patients 
experience decreased libido, erectile dysfunction, depression, 
fatigue, hot flashes, and reduced quality of life. Untreated 
patients with OPIAD may develop further complications 
such as osteopenia or osteoporosis.37 A number of androgen 
replacement therapy options have been developed; however, 
unfortunately, OPIAD is often unrecognized and underdiag-
nosed. In men with OPIAD, testosterone patch therapy at a 
dose of 7.5 mg/day has been reported to significantly improve 
androgen deficiency symptoms, sexual function, depression 
score, and quality of life.38 Testosterone or estradiol levels 
were found to be below the normal range in men chronically 
taking sustained-action oral opioids for chronic noncancer 
pain. Androgen levels approached the castrate range, with 
consequent severe erectile dysfunction in about 90% of the 
patients. These patients experienced weakness and reduced 
muscular mass, which can increase the risk of bone fracture. 
Moreover, they had reduced levels of dehydroepiandros-
terone sulfate (DHEAS), a marker of generalized adrenal 
insufficiency; two-thirds of cases had DHEAS values below 
age-specific norms, and one-third had values below 15 μg/dL, 
which is the detection limit of laboratory tests. DHEAS 
deficiency was not accompanied by adrenocorticotropic 
hormone (ACTH) deficiency, supporting the hypothesis of 
opioid-induced inhibition of adrenal androgen production, 
rather than reduced ACTH stimulation.39,40 Experimental 
studies have shown that the gonads are directly affected by 
morphine treatment, which modify the expression of testicu-
lar and ovarian estrogen and androgen receptors in rats.41
Besides hypogonadotropic hypogonadism or decreased 
adrenal androgen production, sustained-release opioids also 
induce cortisol deficiency, identified by decreased levels of 
cortisol and decreased cortisol response to corticotropin.42 
Opioids reduce the concentration of corticotropin-releasing 
hormone and the secretion of ACTH from the pituitary. 
However, while sex hormone deficiency causes well-known 
symptoms (known as OPIAD), the clinical significance of 
opioid-induced cortisol deficiency is still unclear and may 
range from fatigue and depression to clinical features that 
mimic adrenocortical failure.43 The interaction between 
glucocorticoids and opioids in nociception is currently an 
objective of scientific research. Evidence suggests a clear 
overlapping between the two analgesic systems: opioids 
regulate glucocorticoid-induced analgesia and glucocorti-
coids regulate opioid-induced analgesia.44
It is still unclear whether or not opioid-induced 
hypogonadism is associated with an increased risk of bone 
fractures.45 Few available data come from studies on addicts 
receiving methadone maintenance treatment (MMT). The 
first report by Pedrazzoni et al46 showed that among male 
chronic heroin users, the more recent the last dose, the more 
likely a low BMD. Abusers, who had their last doses less 
than 2 days before the evaluation showed a significantly 
increased risk of lower vertebral BMD (P,0.05) compared 
with former addicts who were drug-free for 4–24 months 
prior.46 Similarly, in a cohort of participants in an MMT 
program, 83% of enrolled patients had a low BMD, with a 
T-score ,-2.5, as measured by dual-energy X-ray densitom-
etry, and male sex was a significant predictor of low BMD.47 
Therapeutics and Clinical Risk Management 2015:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
520
Coluzzi et al
Recently, BMD and markers of bone turnovers were evaluated in 
83 patients receiving MMT for a median of 11 years. BMD 
was lower than normal (approximately 10% below the popu-
lation mean) only in men, but not in women, while markers 
of bone turnover were normal in both sexes. Men taking 
MMT had a lower serum testosterone level compared with 
controls, with possible increases in the risk of fracture.48 
In aging patients with HIV, heroin use and MMT were 
associated with lower BMD in the lumbar spine in both 
sexes.49,50 According to these findings, the chronic use of 
opioids (methadone) significantly increases the risk of low 
BMD; however, the reported differences among the sexes 
are still difficult to explain. Which factors could contribute 
to the observed increased risk in men? Tobacco smoking, 
a recognized risk factor for osteoporosis and a very com-
mon comorbidity among MMT participants, is unlikely to 
explain the observed differences between sexes, because the 
incidence of active smokers was similar between men and 
women in the reported studies. Perhaps estrogens could be 
critical in men, as in females, for bone homeostasis.51 Differ-
ences in gonadal function need further investigation in order 
to explain the effects of opioids on bone metabolism.
Hypogonadism is a well-recognized factor for lower 
BMD because sexual hormones influence bone mass and 
integrity, and protect against osteoporosis.52 Low serum tes-
tosterone levels have been reported in men taking heroin and 
high-dose MMT, presumably due to the opioid suppression of 
gonadotropin secretion. This effect is reversed by naloxone.53 
Among long-term oral opioid users, the prevalence of 
osteopenia and hypogonadism was significantly higher in 
men than in women – 50% of men versus 21% of premeno-
pausal women had a T-score between -1 and -2.5, whereas 
the prevalence of hypogonadism was more than threefold 
in men than in women (75% versus 21%, respectively).54 
These results showed a higher percentage of hypogonadism 
(75%) compared with osteopenia (50%) in male subjects, 
suggesting that other factors should contribute to the effects 
of opioids on bone quality. However, other studies showed 
exactly the opposite result; in a cohort of 81 male patients 
using opioids, about half of the patients had osteopenia/
osteoporosis, but only 27% were hypogonadal.55 Therefore, 
testosterone levels are not definitive for an increased risk of 
low BMD and related fractures. Additional factors should 
be considered.
To summarize the aforementioned findings, hypogonad-
ism is likely the main cause of osteoporosis in both sexes. 
However, the current knowledge is still inadequate to clarify 
why men are more likely to be affected during the chronic use 
of opioids than women, and by which mechanisms opiates 
exert this effect. Opioid-induced hypogonadism is under-
recognized and undertreated. So, a major lesson we can learn 
from the data is the need for monitoring hormone levels,56 
and for routinely screening BMD57 in all patients during 
chronic opioid therapy. Standards have not been established 
for monitoring and treating opioid-induced hypogonadism or 
hypoadrenalism. Based on the literature and clinical experi-
ence, patients taking opioid therapy equivalent to $100 mg 
of daily morphine should be monitored for the development 
of hypogonadism. Suggested laboratory tests that can be 
useful to check endocrine system function include: total 
and free testosterone levels; and blood concentrations of sex 
hormone-binding globulin, LH, FSH, DHEAS, and estradiol 
(in women).42,57
Not all opioids produce equal 
effects on the hypothalamic–
pituitary–gonadal axis
In view of the well-known suppressive effects, clinicians 
should evaluate the different abilities of individual opioids 
on their ability to affect the hypothalamic–pituitary–gonadal 
axis (and in individual patients). Preclinical studies on male 
rats found no difference among the opioids morphine, fen-
tanyl, tramadol, and buprenorphine on plasma testosterone 
levels at 4 hours after a single injection; however, testosterone 
was significantly reduced when animals were treated with 
high concentrations of the opioids tested.58 Brain testosterone 
levels were significantly reduced when compared to control 
(saline) 4 hours after morphine, fentanyl, or tramadol injec-
tion, but not after buprenorphine (Figure 2). It has been 
speculated that the different effect of buprenorphine might be 
due to the relatively slow initial binding to MOR and longer 
receptor occupancy when compared with other opioids.58
Similar findings have been reported in clinical stud-
ies on patients treated with intrathecal morphine and with 
the long-term use of buprenorphine. Epidural morphine 
was shown to decrease testosterone plasma levels in both 
sexes, which was completely reversed after the interrup-
tion of therapy, and this was related to a peripheral action 
(on the testis in men and in the adrenals in men and women). 
In contrast, when patients were treated with buprenorphine 
for 6 months, only free testosterone was reported to be lower 
than baseline in men – an effect paralleled by the increase of 
sex hormone binding globuline – while no effects were 
recorded in any of the hormones in women.59 In women of dif-
ferent reproductive ages, the hormonal effects of transdermal 
buprenorphine have been reported to be negligible in clinical 
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Figure 2 Opioid-induced effects on brain testosterone.
Notes: *Diencephalic brain testosterone levels following the subcutaneous administration of morphine (10 mg/kg), fentanyl (0.1 mg/kg), tramadol (40 mg/kg), or buprenorphine 
(0.1 mg/kg). (A) Brain testosterone levels were lower than control in all groups except buprenorphine at 4 hours.  (B) no differences were observed between groups in 
brain testosterone levels at 24 hours. Reprinted from neuroscience, 140(3), Ceccarelli i, De padova AM, Fiorenzani p, Massafra C, Aloisi AM; Single opioid administration 
modifies gonadal steroids in both the CNS and plasma of male rats, 929–937, Copyright (2006), with permission from Elsevier.58
Abbreviation: h, hours.
practice, with no side effects suggestive of hypogonadism. 
Total and free testosterone were not reduced during stan-
dard treatment with the buprenorphine transdermal system, 
35 μg/hour administered every 72 hours.60
Tapentadol is an innovative opioid with two mechanisms 
of action: MOR agonism (with a 50-fold lower affinity 
for the human MOR than morphine); and norepinephrine 
reuptake inhibition (the first of a new pharmacological 
class named MOR/noradrenaline reuptake inhibitor). The 
results from three randomized placebo-controlled studies 
involving healthy subjects or patients with osteoarthritis 
knee pain showed that the effects of tapentadol treatment on 
testosterone and gonadotropin (LH and/or FSH) levels were 
minimal and not considered to be clinically relevant. The 
reason for these findings is not completely clear; however, 
it is likely that a difference in the effects of tapentadol on 
sexual hormones when compared with morphine may be 
related to the dual mechanism of action of tapentadol (opioid 
and nonopioid).61 The contribution of the nonopioid compo-
nent to analgesia results in a mechanistic “opioid-sparing” 
effect and the nonopioid component might mitigate against 
some opioid-induced adverse effects. Sufficient clinical 
or preclinical data on this point are lacking; however, it is 
clear that the lower the MOR activity, the lower the negative 
impact on the hypothalamic–pituitary–gonadal axis.
Conclusion
Chronic pain can be managed by using analgesic drugs 
and nonpharmacological techniques. Opioids are currently 
the cornerstone in the pharmacologic treatment of severe 
chronic pain. However, in addition to the desired analgesic 
effect, they lead to a number of side effects, such as nausea, 
vomiting, constipation, respiratory depression, sedation, and 
cognitive impairment. The onset of intolerable side effects 
often leads to the decision to reduce drug dosage, raising the 
risk of inadequate analgesia, leading to the establishment of 
a dangerous “vicious cycle”.5 However, besides the well-
known undesirable adverse effects, there are other clinically 
less visible and still poorly understood nonanalgesic actions, 
such as their effects on bone metabolism. These are less 
studied and are underdiagnosed.62 The risk of misunderstand-
ing these relevant aspects of chronic opioid treatment may 
lead to a number of comorbidities, such as hypogonadism 
and osteoporosis. Different studies have shown that both 
men and women chronically treated with opioids are at an 
increased risk for a reduction in BMD. Preclinical studies 
have shown that some opioids have a lower osteoporotic 
effect than others; however, it is still unclear which opioids 
are less likely to cause endocrine dysfunction and posses 
the best profile for minimizing the negative effects on bone 
metabolism. Similarly, more studies are needed to identify 
which patients need to be screened, what length of time is 
needed to develop endocrine dysfunction after starting opi-
oids, and if these effects are reversible after stopping opioid 
therapy. It is reasonable to think that analgesics that have a 
lower contribution of MOR activity to the overall analgesic 
effect could represent the best choice in the delicate balance 
between analgesic efficacy and adverse effects. If further 
studies confirm this hypothesis, the choice of analgesic drug 
for chronic pain management should also take into consid-
eration this particular endocrinological–metabolic aspect, 
especially in predisposed, frail, and elderly patients.
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